How the pharmaceutical giant automated rebates with Evolve and massively reduced their turnaround time
MSD
Merck Sharp & Dohme (MSD) is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. MSD produced the first tuberculosis vaccine in 1944, and continues to bring a number of pioneering medicines in areas such as heart disease and cancer. As the healthcare needs of the world evolve, so does their pipeline - with the UK making forward investments in areas such as dementia and antimicrobial resistance. MSD has offices in 140 countries and aims to improve the health and wellbeing of people and animals around the world.
The challenge
MSD used a massive spreadsheet to validate all rebate claims manually. The sheet was close to reaching Excel's line limit and had a high risk of failure.
The spreadsheet was not linked with any other system and was built and maintained by one person. As a result, the rebate validation turnaround was very slow, seriously affecting the whole process. Nor was there any auditability or control. It was hardbound to manual intervention.
How we helped
MSD partnered with Evolve to build a bespoke Cloud-based solution – a complete automated end-to-end rebate platform.
Evolve provided a data specialist for data cleansing and data transformation and built a claims validation module to compare claims from distributors against deals saved on the system. We implemented customised screens and enhanced reporting functionality as well as a smart dashboard for real-time performance task management.
The results
- Instant rebate validation with turnaround time reduced massively
- Full control over data quality and accuracy
- Little to no manual intervention required
- More efficient deal maintenance
- Greater transparency providing protection for the customer and the business
- Risks associated with a single person maintaining the process completely removed
- Full auditability and reporting
Testimonial
"Our rebate validation process has been improved significantly, thanks to Evolve."
Peter O’Shaughnessy, Associate Director Financial Planning & Analysis